Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort

Raquel Palacios-Baena Z., Gutierrez-Gutierrez B., Calbo E., Almirante B., Viale P., Oliver A., ...Daha Fazla

CLINICAL INFECTIOUS DISEASES, cilt.65, sa.10, ss.1615-1623, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 65 Konu: 10
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1093/cid/cix606
  • Sayfa Sayıları: ss.1615-1623


Background. There is little information about the efficacy of active alternative drugs to carbapenems except beta-lactam/beta-lactamase inhibitors for the treatment of bloodstream infections (BSIs) due to extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E). The objective of this study was to assess the outcomes of patients with BSI due to ESBL-E who received empiric therapy with such drugs (other active drugs [OADs]) or carbapenems.